We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Recommends Suspending 100 Generic Meds After Data Irregularities Found in Bioequivalence Studies
EMA Recommends Suspending 100 Generic Meds After Data Irregularities Found in Bioequivalence Studies
About 100 generic medicines are likely to get their European marketing authorizations yanked following revelations of flaws in their bioequivalence studies conducted at one particular contract research organization.